<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">
<pdf2xml producer="poppler" version="23.04.0">
<page number="1" position="absolute" top="0" left="0" height="782" width="593">
	<fontspec id="font0" size="9" family="AdvC2866" color="#000000"/>
	<fontspec id="font1" size="9" family="AdvPS586B" color="#000000"/>
	<fontspec id="font2" size="9" family="AdvP4C4E74" color="#000000"/>
	<fontspec id="font3" size="9" family="AdvC2870" color="#000000"/>
	<fontspec id="font4" size="6" family="AdvC2870" color="#000000"/>
	<fontspec id="font5" size="6" family="AdvC2866" color="#000000"/>
	<fontspec id="font6" size="10" family="AdvSMyr-SB" color="#000000"/>
	<fontspec id="font7" size="9" family="AdvC2867" color="#000000"/>
	<fontspec id="font8" size="8" family="AdvPSMy-B" color="#000000"/>
	<fontspec id="font9" size="8" family="AdvPSMy-R" color="#000000"/>
	<fontspec id="font10" size="7" family="AdvPSMy-R" color="#000000"/>
<text top="50" left="45" width="243" height="8" font="font0" id="p1_t1" reading_order_no="1" segment_no="1" tag_type="text">immunization, whereas serious adverse events were moni-</text>
<text top="61" left="45" width="140" height="8" font="font0" id="p1_t2" reading_order_no="2" segment_no="1" tag_type="text">tored throughout the 12-mo study.</text>
<text top="72" left="54" width="234" height="8" font="font0" id="p1_t3" reading_order_no="3" segment_no="2" tag_type="text">Blood was collected at screening, on immunization days, 14</text>
<text top="83" left="45" width="243" height="8" font="font0" id="p1_t4" reading_order_no="4" segment_no="2" tag_type="text">d after each immunization, and on study days 90, 180, 272,</text>
<text top="94" left="45" width="243" height="8" font="font0" id="p1_t5" reading_order_no="5" segment_no="2" tag_type="text">and 364 to determine complete blood count, alanine amino-</text>
<text top="105" left="45" width="162" height="8" font="font0" id="p1_t6" reading_order_no="6" segment_no="2" tag_type="text">transferase (ALT), and serum creatinine.</text>
<text top="116" left="54" width="234" height="8" font="font0" id="p1_t7" reading_order_no="7" segment_no="3" tag_type="text">Adverse events were graded by severity and judged for</text>
<text top="127" left="45" width="243" height="8" font="font0" id="p1_t8" reading_order_no="8" segment_no="3" tag_type="text">relatedness to study vaccines. Mild adverse events were easily</text>
<text top="138" left="45" width="243" height="8" font="font0" id="p1_t9" reading_order_no="9" segment_no="3" tag_type="text">tolerated, causing minimal discomfort and not interfering</text>
<text top="149" left="45" width="243" height="8" font="font0" id="p1_t10" reading_order_no="10" segment_no="3" tag_type="text">with daily activities. Moderate adverse events were sufﬁciently</text>
<text top="160" left="45" width="243" height="8" font="font0" id="p1_t11" reading_order_no="11" segment_no="3" tag_type="text">discomforting to interfere with normal activities. Severe</text>
<text top="171" left="45" width="243" height="8" font="font0" id="p1_t12" reading_order_no="12" segment_no="3" tag_type="text">adverse events prevented normal daily activities. Swelling,</text>
<text top="182" left="45" width="243" height="8" font="font0" id="p1_t13" reading_order_no="13" segment_no="3" tag_type="text">erythema, fever, and limitation of arm motion had speciﬁc</text>
<text top="193" left="45" width="243" height="8" font="font0" id="p1_t14" reading_order_no="14" segment_no="3" tag_type="text">deﬁnitions not based on interference with daily activities.</text>
<text top="204" left="45" width="243" height="8" font="font0" id="p1_t15" reading_order_no="15" segment_no="3" tag_type="text">Injection site swelling and erythema were graded based on</text>
<text top="215" left="45" width="243" height="8" font="font0" id="p1_t16" reading_order_no="16" segment_no="3" tag_type="text">their widest dimension: mild, . 0–20 mm; moderate, . 20–50</text>
<text top="226" left="45" width="243" height="8" font="font0" id="p1_t17" reading_order_no="17" segment_no="3" tag_type="text">mm; and severe, . 50 mm. Fever was classiﬁed as severe if the</text>
<text top="237" left="45" width="87" height="8" font="font0" id="p1_t18" reading_order_no="18" segment_no="3" tag_type="text">oral temperature was</text>
<text top="237" left="142" width="146" height="8" font="font0" id="p1_t19" reading_order_no="19" segment_no="3" tag_type="text">39 8 C , whereas severe limitation of</text>
<text top="248" left="45" width="243" height="9" font="font0" id="p1_t20" reading_order_no="20" segment_no="3" tag_type="text">arm motion was classiﬁed as abduction limited to 30 8 . For</text>
<text top="260" left="45" width="243" height="8" font="font0" id="p1_t21" reading_order_no="21" segment_no="3" tag_type="text">laboratory tests, toxicity grading was adapted to normal</text>
<text top="271" left="45" width="240" height="8" font="font0" id="p1_t22" reading_order_no="22" segment_no="3" tag_type="text">reference ranges determined for the local adult population.</text>
<text top="282" left="54" width="234" height="9" font="font3" id="p1_t23" reading_order_no="23" segment_no="6" tag_type="text">Antibody responses to MSP-1 42 . Antibody responses to</text>
<text top="293" left="45" width="243" height="9" font="font0" id="p1_t24" reading_order_no="24" segment_no="6" tag_type="text">MSP-1 42 were measured by ELISA [6]. Brieﬂy, cGMP-puriﬁed</text>
<text top="304" left="45" width="243" height="9" font="font0" id="p1_t25" reading_order_no="25" segment_no="6" tag_type="text">bulk MSP-1 42 [3] was used as plate antigen, and serial</text>
<text top="315" left="45" width="243" height="8" font="font0" id="p1_t26" reading_order_no="26" segment_no="6" tag_type="text">dilutions of each sample, along with positive and negative</text>
<text top="326" left="45" width="243" height="8" font="font0" id="p1_t27" reading_order_no="27" segment_no="6" tag_type="text">controls, were made to yield a linear range of dilutions that</text>
<text top="337" left="45" width="243" height="8" font="font0" id="p1_t28" reading_order_no="28" segment_no="6" tag_type="text">could be analyzed with curve-ﬁtting software (SoftMax Pro</text>
<text top="348" left="45" width="243" height="8" font="font0" id="p1_t29" reading_order_no="29" segment_no="6" tag_type="text">v4.1, Molecular Devices, Sunnyvale, California, United States)</text>
<text top="359" left="45" width="243" height="8" font="font0" id="p1_t30" reading_order_no="30" segment_no="6" tag_type="text">to calculate the theoretical dilution that would give an optical</text>
<text top="370" left="45" width="243" height="8" font="font0" id="p1_t31" reading_order_no="31" segment_no="6" tag_type="text">density of 1.0 in the endpoint assay; the reciprocals of these</text>
<text top="381" left="45" width="243" height="8" font="font0" id="p1_t32" reading_order_no="32" segment_no="6" tag_type="text">calculated dilutions were reported as the sample titers. To</text>
<text top="392" left="45" width="243" height="10" font="font0" id="p1_t33" reading_order_no="33" segment_no="6" tag_type="text">compare antibody responses to different alleles of MSP-1 42 ,</text>
<text top="403" left="45" width="243" height="10" font="font0" id="p1_t34" reading_order_no="34" segment_no="6" tag_type="text">recombinant MSP-1 42 of the 3D7 and FVO alleles were</text>
<text top="414" left="45" width="243" height="8" font="font0" id="p1_t35" reading_order_no="35" segment_no="6" tag_type="text">prepared as described previously [6,13]. Preparation of</text>
<text top="425" left="45" width="93" height="10" font="font0" id="p1_t36" reading_order_no="36" segment_no="6" tag_type="text">recombinant MSP-1 42</text>
<text top="425" left="145" width="143" height="8" font="font0" id="p1_t37" reading_order_no="37" segment_no="6" tag_type="text">of the Camp/FUP allele will be</text>
<text top="436" left="45" width="82" height="8" font="font0" id="p1_t38" reading_order_no="38" segment_no="6" tag_type="text">described elsewhere.</text>
<text top="447" left="54" width="234" height="10" font="font3" id="p1_t39" reading_order_no="39" segment_no="9" tag_type="text">Antibody responses to fragments of MSP-1 42 . MSP-1 frag-</text>
<text top="458" left="45" width="243" height="8" font="font0" id="p1_t40" reading_order_no="40" segment_no="9" tag_type="text">ment-speciﬁc antibody responses were assessed by a standard</text>
<text top="470" left="45" width="243" height="9" font="font0" id="p1_t41" reading_order_no="41" segment_no="9" tag_type="text">ELISA [6]. Fragments of MSP-1 42 corresponding to MSP-1 19</text>
<text top="481" left="45" width="243" height="8" font="font0" id="p1_t42" reading_order_no="42" segment_no="9" tag_type="text">(3D7 and FVO alleles) and the two epidermal growth factor</text>
<text top="492" left="45" width="243" height="9" font="font0" id="p1_t43" reading_order_no="43" segment_no="9" tag_type="text">(EGF)-like domains that comprise MSP-1 19, EGF1 (3D7-Camp/</text>
<text top="503" left="45" width="243" height="8" font="font0" id="p1_t44" reading_order_no="44" segment_no="9" tag_type="text">FUP [14] and FVO alleles) and EGF2 (3D7 and FVO-Camp/</text>
<text top="514" left="45" width="243" height="8" font="font0" id="p1_t45" reading_order_no="45" segment_no="9" tag_type="text">FUP alleles), were expressed as glutathione S-transferase</text>
<text top="525" left="45" width="199" height="8" font="font0" id="p1_t46" reading_order_no="46" segment_no="9" tag_type="text">fusion proteins and puriﬁed to homogeneity [13].</text>
<text top="543" left="45" width="55" height="10" font="font6" id="p1_t47" reading_order_no="47" segment_no="12" tag_type="title">Sample Size</text>
<text top="555" left="45" width="243" height="8" font="font0" id="p1_t48" reading_order_no="48" segment_no="13" tag_type="text">This phase I trial was not powered to detect differences</text>
<text top="566" left="45" width="243" height="8" font="font0" id="p1_t49" reading_order_no="49" segment_no="13" tag_type="text">between groups. A sample size of 20 malaria vaccine</text>
<text top="577" left="45" width="243" height="8" font="font0" id="p1_t50" reading_order_no="50" segment_no="13" tag_type="text">recipients was based on general acceptance of this size for</text>
<text top="589" left="45" width="243" height="8" font="font0" id="p1_t51" reading_order_no="51" segment_no="13" tag_type="text">initial assessment of safety, tolerability, and immunogenicity</text>
<text top="600" left="45" width="243" height="8" font="font0" id="p1_t52" reading_order_no="52" segment_no="13" tag_type="text">of investigational vaccines. Inclusion of a comparator vaccine</text>
<text top="611" left="45" width="243" height="8" font="font0" id="p1_t53" reading_order_no="53" segment_no="13" tag_type="text">group of 20 permitted broad estimates of the incidence of</text>
<text top="622" left="45" width="243" height="8" font="font0" id="p1_t54" reading_order_no="54" segment_no="13" tag_type="text">local and general side effects and immune responses to</text>
<text top="633" left="45" width="70" height="8" font="font0" id="p1_t55" reading_order_no="55" segment_no="13" tag_type="text">natural infection.</text>
<text top="651" left="45" width="68" height="10" font="font6" id="p1_t56" reading_order_no="56" segment_no="16" tag_type="title">Randomization</text>
<text top="663" left="45" width="243" height="8" font="font0" id="p1_t57" reading_order_no="57" segment_no="17" tag_type="text">Randomization was done in blocks of four without stratiﬁ-</text>
<text top="674" left="45" width="243" height="8" font="font0" id="p1_t58" reading_order_no="58" segment_no="17" tag_type="text">cation. Opaque, sealed randomization envelopes containing</text>
<text top="685" left="45" width="243" height="8" font="font0" id="p1_t59" reading_order_no="59" segment_no="17" tag_type="text">sequential codes linked to vaccine assignment were prepared</text>
<text top="696" left="45" width="243" height="8" font="font0" id="p1_t60" reading_order_no="60" segment_no="17" tag_type="text">by Statistics Collaborative (Washington, D. C., United States).</text>
<text top="707" left="45" width="243" height="8" font="font0" id="p1_t61" reading_order_no="61" segment_no="17" tag_type="text">Codes were assigned in the order that participants arrived at</text>
<text top="719" left="45" width="173" height="8" font="font0" id="p1_t62" reading_order_no="62" segment_no="17" tag_type="text">the clinic on the day of ﬁrst immunization.</text>
<text top="301" left="306" width="38" height="10" font="font6" id="p1_t63" reading_order_no="65" segment_no="7" tag_type="title">Blinding</text>
<text top="313" left="306" width="243" height="8" font="font0" id="p1_t64" reading_order_no="66" segment_no="8" tag_type="text">The only people at the study site with access to the</text>
<text top="324" left="306" width="243" height="8" font="font0" id="p1_t65" reading_order_no="67" segment_no="8" tag_type="text">randomization codes during the study were two study</text>
<text top="336" left="306" width="243" height="8" font="font0" id="p1_t66" reading_order_no="68" segment_no="8" tag_type="text">pharmacists, who had no contact with study participants</text>
<text top="347" left="306" width="243" height="8" font="font0" id="p1_t67" reading_order_no="69" segment_no="8" tag_type="text">and did not reveal vaccine assignments to anyone else. Study</text>
<text top="358" left="306" width="243" height="8" font="font0" id="p1_t68" reading_order_no="70" segment_no="8" tag_type="text">participants and investigators who assessed outcomes were</text>
<text top="369" left="306" width="243" height="8" font="font0" id="p1_t69" reading_order_no="71" segment_no="8" tag_type="text">blinded to vaccine assignment. Vaccines were prepared in a</text>
<text top="380" left="306" width="243" height="8" font="font0" id="p1_t70" reading_order_no="72" segment_no="8" tag_type="text">secure room communicating with the vaccine administration</text>
<text top="391" left="306" width="243" height="8" font="font0" id="p1_t71" reading_order_no="73" segment_no="8" tag_type="text">room through a small window with a sliding door. Recon-</text>
<text top="402" left="306" width="243" height="8" font="font0" id="p1_t72" reading_order_no="74" segment_no="8" tag_type="text">stituted FMP1/AS02A is off-white and Imovax is pink. To</text>
<text top="413" left="306" width="243" height="8" font="font0" id="p1_t73" reading_order_no="75" segment_no="8" tag_type="text">reduce potential bias, syringes containing the vaccines were</text>
<text top="424" left="306" width="243" height="8" font="font0" id="p1_t74" reading_order_no="76" segment_no="8" tag_type="text">wrapped with opaque tape to conceal their contents from</text>
<text top="435" left="306" width="243" height="8" font="font0" id="p1_t75" reading_order_no="77" segment_no="8" tag_type="text">participants and vaccinators. Vaccines were administered by</text>
<text top="446" left="306" width="231" height="8" font="font0" id="p1_t76" reading_order_no="78" segment_no="8" tag_type="text">physicians who did not participate in assessing outcomes.</text>
<text top="465" left="306" width="87" height="10" font="font6" id="p1_t77" reading_order_no="79" segment_no="10" tag_type="title">Ethical Compliance</text>
<text top="477" left="306" width="243" height="8" font="font0" id="p1_t78" reading_order_no="80" segment_no="11" tag_type="text">The protocol was approved by institutional review boards of</text>
<text top="488" left="306" width="243" height="8" font="font0" id="p1_t79" reading_order_no="81" segment_no="11" tag_type="text">the University of Bamako Faculty of Medicine, the University</text>
<text top="499" left="306" width="243" height="8" font="font0" id="p1_t80" reading_order_no="82" segment_no="11" tag_type="text">of Maryland, the United States Army Surgeon General, and</text>
<text top="510" left="306" width="243" height="8" font="font0" id="p1_t81" reading_order_no="83" segment_no="11" tag_type="text">the National Institute of Allergy and Infectious Disease.</text>
<text top="521" left="306" width="243" height="8" font="font0" id="p1_t82" reading_order_no="84" segment_no="11" tag_type="text">Separate written informed consent was obtained for screen-</text>
<text top="533" left="306" width="243" height="8" font="font0" id="p1_t83" reading_order_no="85" segment_no="11" tag_type="text">ing and for enrollment. Consent of illiterate participants was</text>
<text top="544" left="306" width="243" height="8" font="font0" id="p1_t84" reading_order_no="86" segment_no="11" tag_type="text">documented by their thumbprints and by signatures of</text>
<text top="555" left="306" width="243" height="8" font="font0" id="p1_t85" reading_order_no="87" segment_no="11" tag_type="text">independent witnesses. Permission to conduct the study was</text>
<text top="566" left="306" width="243" height="8" font="font0" id="p1_t86" reading_order_no="88" segment_no="11" tag_type="text">granted by the Republic of Mali Ministry of Health, and the</text>
<text top="577" left="306" width="243" height="8" font="font0" id="p1_t87" reading_order_no="89" segment_no="11" tag_type="text">trial was monitored by the United States Army Medical</text>
<text top="588" left="306" width="243" height="8" font="font0" id="p1_t88" reading_order_no="90" segment_no="11" tag_type="text">Materiel Development Activity and the World Health Organ-</text>
<text top="599" left="306" width="29" height="8" font="font0" id="p1_t89" reading_order_no="91" segment_no="11" tag_type="text">ization.</text>
<text top="617" left="306" width="87" height="10" font="font6" id="p1_t90" reading_order_no="92" segment_no="14" tag_type="title">Statistical Methods</text>
<text top="630" left="306" width="243" height="8" font="font0" id="p1_t91" reading_order_no="93" segment_no="15" tag_type="text">Adverse event rates were analyzed using SAS version 8.2 (SAS</text>
<text top="641" left="306" width="243" height="8" font="font0" id="p1_t92" reading_order_no="94" segment_no="15" tag_type="text">Institute, Cary, North Carolina, United States). Fisher’s exact</text>
<text top="652" left="306" width="243" height="8" font="font0" id="p1_t93" reading_order_no="95" segment_no="15" tag_type="text">test was used to compare rates between vaccine groups.</text>
<text top="663" left="306" width="243" height="10" font="font0" id="p1_t94" reading_order_no="96" segment_no="15" tag_type="text">Conﬁdence intervals (CIs) for geometric mean MSP-1 42</text>
<text top="674" left="306" width="243" height="10" font="font0" id="p1_t95" reading_order_no="97" segment_no="15" tag_type="text">antibody titers were estimated by using log 10 -transformed</text>
<text top="685" left="306" width="243" height="8" font="font0" id="p1_t96" reading_order_no="98" segment_no="15" tag_type="text">values, calculating the 95% CI based on the normal</text>
<text top="696" left="306" width="243" height="8" font="font0" id="p1_t97" reading_order_no="99" segment_no="15" tag_type="text">distribution, and then converting the limits to the original</text>
<text top="707" left="306" width="243" height="8" font="font0" id="p1_t98" reading_order_no="100" segment_no="15" tag_type="text">scale for presentation. All tests were two-sided, and no</text>
<text top="719" left="306" width="243" height="8" font="font0" id="p1_t99" reading_order_no="101" segment_no="15" tag_type="text">correction of p -values was made for additional analyses. MSP-</text>
<text top="264" left="306" width="73" height="7" font="font8" id="p1_t100" reading_order_no="63" segment_no="4" tag_type="text">Figure 1. Trial Profile</text>
<text top="278" left="306" width="120" height="7" font="font10" id="p1_t101" reading_order_no="64" segment_no="5" tag_type="text">doi:10.1371/journal.pctr.0010034.g001</text>
<text top="742" left="45" width="85" height="7" font="font9" id="p1_t102" reading_order_no="102" segment_no="18" tag_type="text">www.plosclinicaltrials.org</text>
<text top="742" left="471" width="78" height="7" font="font9" id="p1_t103" reading_order_no="104" segment_no="19" tag_type="text">November | 2006 | e34</text>
<text top="742" left="289" width="16" height="7" font="font9" id="p1_t104" reading_order_no="103" segment_no="20" tag_type="text">0004</text>
<text top="26" left="471" width="78" height="7" font="font9" id="p1_t105" reading_order_no="0" segment_no="0" tag_type="title">Malaria Vaccine in Mali</text>
</page>
</pdf2xml>
